Thioridazine
Thioridazine is an older antipsychotic medicine reserved for people with schizophrenia who haven't responded well to other antipsychotics, because it can cause serious heart rhythm problems.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 5 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Thioridazine (Mellaril) is an older phenothiazine antipsychotic, on the U.S. market since about 1962 and available generically, now a rarely used last resort for schizophrenia after at least two other antipsychotics have failed or proved intolerable. It causes less stiffness than its relatives, but drowsiness early on, dry mouth, constipation and dizziness on standing are common. Its boxed warning says it lengthens the QTc interval (the heart’s electrical recovery time) in a dose-related way and has been linked to Torsades de pointes (a dangerous rhythm) and sudden death. Expect ECG and potassium checks, and get help right away for dizziness, palpitations or fainting.
Clinical pearls
- Never combine it with fluoxetine, paroxetine, fluvoxamine, propranolol or pindolol, which all raise thioridazine levels.
- Have your pharmacist screen every new prescription, because other drugs that prolong the QTc add to its heart risk.
- People known to have genetically low CYP2D6 enzyme activity should not take it, so mention any such test result.
- A bout of vomiting or diarrhea can lower potassium, which raises the rhythm risk, so tell your prescriber.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Thioridazine can cause a dangerous heart rhythm problem and sudden death. It lengthens the QTc interval in a dose-related way and has been linked to Torsades de pointes. Because of this, it is reserved for people with schizophrenia who haven't responded to other antipsychotics.
Older adults with dementia-related psychosis who take antipsychotics have a higher risk of death. In trials, about 4.5% of drug-treated patients died versus about 2.6% on placebo. Most deaths were heart-related, such as heart failure or sudden death, or infections such as pneumonia. Thioridazine is not approved for dementia-related psychosis.
Watch for dizziness, palpitations or fainting, and report them right away.
Patient information guide A plain-language walkthrough of Thioridazine, written from its FDA label.
What Thioridazine is used for
▾
Thioridazine is a phenothiazine antipsychotic with one approved use.
- Thioridazine hydrochloride tablets manage schizophrenia in people who haven't responded adequately to other antipsychotic drugs, either because those drugs weren't effective enough or caused intolerable side effects.
- The label strongly recommends at least two trials of different antipsychotics first.
- Its effectiveness in treatment-resistant schizophrenia hasn't been systematically studied in controlled trials.
How Thioridazine works
▾
Thioridazine works much like other phenothiazine antipsychotics, but it tends to cause fewer stiffness and tremor-type movement side effects.
It also slows the heart's electrical recovery (the QTc interval) in a dose-related way. That effect is the reason for its strict limits on use.
Thioridazine dosage
▾
Thioridazine hydrochloride tablets are taken by mouth, with the daily total split into two to four doses. Your prescriber will start low, raise the dose gradually if needed, and later try to lower it to the smallest dose that keeps symptoms controlled.
- Dosing for children with schizophrenia who haven't responded to other medicines is based on body weight and divided into doses.
- Follow your prescriber and the label exactly.
Dosing details from the FDA-approved label
From the Thioridazine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Adults (schizophrenic patients)
- The usual starting dose is 50 mg to 100 mg three times a day, with a gradual increment if necessary
- Once effective control of symptoms has been achieved, the dosage may be reduced gradually to determine the minimum maintenance dose
- The total daily dosage ranges from 200 mg to 800 mg, divided into two to four doses
- Maximum: 800 mg daily
- Dosage must be individualized and the smallest effective dosage determined for each patient; reserved for patients who fail to respond adequately to other antipsychotic drugs
- Pediatric patients with schizophrenia who are unresponsive to other agents
- The recommended initial dose is 0.5 mg/kg/day given in divided doses
- Dosage may be increased gradually until optimum therapeutic effect is obtained
- Maximum: 3 mg/kg/day
- Dosage must be individualized and the smallest effective dosage determined for each patient
Read the label’s full dosing text
DOSAGE AND ADMINISTRATION Since thioridazine hydrochloride tablets are associated with a dose related prolongation of the QTc interval, which is a potentially life threatening event, its use should be reserved for schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Dosage must be individualized and the smallest effective dosage should be determined for each patient (see INDICATIONS and WARNINGS ). Adults The usual starting dose for adult schizophrenic patients is 50 mg to 100 mg three times a day, with a gradual increment to a maximum of 800 mg daily if necessary. Once effective control of symptoms has been achieved, the dosage may be reduced gradually to determine the minimum maintenance dose. The total daily dosage ranges from 200 mg to 800 mg, divided into two to four doses. Pediatric Patients For pediatric patients with schizophrenia who are unresponsive to other agents, the recommended initial dose is 0.5 mg/kg/day given in divided doses. Dosage may be increased gradually until optimum therapeutic effect is obtained or the maximum dose of 3 mg/kg/day has been reached.
Read the full Dosage and Administration section on DailyMed →
Thioridazine side effects
▾
Most side effects at recommended doses are mild and temporary.
Common side effects
- Drowsiness, especially early in treatment
- Dry mouth
- Blurred vision
- Constipation
- Nausea, vomiting or diarrhea
- Stuffy nose
- Swelling in the hands or feet
- Breast enlargement or milk discharge, missed periods, or trouble with ejaculation
- Drowsiness, which often eases with time or a lower dose
- Breast engorgement, milk discharge, missed periods, or trouble with ejaculation
- Swelling in the extremities (peripheral edema)
When to get medical help
- Get help right away if you have dizziness, a racing or irregular heartbeat (palpitations), or fainting. These can signal a dangerous heart rhythm called Torsades de pointes.
- Call your doctor or get urgent care for high fever, severe muscle stiffness, confusion, or an irregular pulse or blood pressure. These can be signs of neuroleptic malignant syndrome.
- Tell your doctor if you notice uncontrolled movements of the tongue, face, mouth or jaw. This can be tardive dyskinesia and may be permanent.
- Report signs of blood or liver problems seen with phenothiazines, such as jaundice (yellowing of skin or eyes) or fever with infection-like symptoms.
- Be careful about falls. Thioridazine can cause sleepiness and a drop in blood pressure when you stand.
Thioridazine warnings and precautions
▾
- Heart rhythm danger: It can lengthen the QTc interval and cause Torsades de pointes and sudden death. Risk is higher with a slow heartbeat, low potassium, other QT-prolonging drugs, congenital long QT, or low CYP2D6 activity.
- Monitoring: A baseline ECG and potassium check are recommended. It should not be started if the QTc is over 450 msec and should be stopped if it goes over 500 msec.
- Dementia: Higher risk of death in older adults with dementia-related psychosis; it is not approved for this use.
- Tardive dyskinesia: Potentially irreversible involuntary movements, with risk rising with longer treatment and higher total dose.
- Neuroleptic malignant syndrome: A rare, potentially fatal reaction.
- Falls: Sleepiness and low blood pressure can lead to falls and injuries.
Thioridazine interactions
▾
Several drugs raise thioridazine levels or add to its heart effects, so combinations need great care.
- Fluoxetine and paroxetine: block the enzyme that clears thioridazine, raising its levels.
- Fluvoxamine, propranolol and pindolol: raise thioridazine levels and should not be combined with it.
- Other QTc-prolonging drugs: heart effects add up, so use is contraindicated.
- Alcohol, opioids, barbiturates and anesthetics: sedation can be stronger, and severe breathing depression has been reported with a high-dose barbiturate.
- Atropine and phosphorus insecticides: effects can be strengthened.
Interactions listed in the FDA-approved label
From the Thioridazine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Drugs that inhibit cytochrome P450 2D6 (e.g., fluoxetine and paroxetine) and reduced P450 2D6 activity: Metabolism of thioridazine is appreciably inhibited, giving elevated thioridazine levels that would be expected to augment QTc interval prolongation and may increase the risk of serious, potentially fatal cardiac arrhythmias such as Torsades de pointes type arrhythmias. Coadministration of drugs that inhibit P450 2D6 with thioridazine, and use in patients known to have reduced P450 2D6 activity (about 7% of the normal population), are contraindicated.
- Fluvoxamine: Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine (25 mg b.i.d. for one week) in ten male inpatients with schizophrenia. Fluvoxamine and thioridazine should not be coadministered.
- Propranolol: Concurrent administration of propranolol (100 mg to 800 mg daily) has been reported to produce increases in plasma levels of thioridazine (approximately 50% to 400%) and its metabolites (approximately 80% to 300%). Propranolol and thioridazine should not be coadministered.
- Pindolol: Concurrent administration has resulted in moderate, dose related increases in serum levels of thioridazine and two of its metabolites, as well as higher than expected serum pindolol levels. Pindolol and thioridazine should not be coadministered.
- Other drugs that prolong the QTc interval: There are no studies of coadministration, but it is expected to produce additive prolongation of the QTc interval. Such use is contraindicated.
Read the label’s full interactions text
Drug Interactions Reduced cytochrome P450 2D6 isozyme activity, drugs which inhibit this isozyme (e.g., fluoxetine and paroxetine), and certain other drugs (e.g., fluvoxamine, propranolol, and pindolol) appear to appreciably inhibit the metabolism of thioridazine. The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as Torsades de pointes type arrhythmias. Such an increased risk may result also from the additive effect of coadministering thioridazine with other agents that prolong the QTc interval. Therefore, thioridazine is contraindicated with these drugs as well as in patients, comprising about 7% of the normal population, who are known to have a genetic defect leading to reduced levels of activity of P450 2D6 (see WARNINGS and CONTRAINDICATIONS ). Drugs That Inhibit Cytochrome P450 2D6 In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg oral dose of thioridazine produced a 2.4-fold higher C max and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared to rapid hydroxylators. The rate of debrisoquin hydroxylation is felt to depend on the level of cytochrome P450 2D6 isozyme activity. Thus, this study suggests that drugs that inhibit P450 2D6 or the presence of reduced activity levels of this isozyme will produce elevated plasma levels of thioridazine. Therefore, the coadministration of drugs that inhibit P450 2D6 with thioridazine and the use of thioridazine in patients known to have reduced activity of P450 2D6 are contraindicated. Drugs That Reduce the Clearance of Thioridazine Through Other Mechanisms Fluvoxamine The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Thioridazine
▾
- Not for people with congenital long QT syndrome or a history of irregular heart rhythms.
- Not for people known to have low CYP2D6 enzyme activity.
- Not for severe central nervous system depression or coma.
- Not for extreme high or low blood pressure heart disease.
- Tell your doctor if you have a slow heartbeat or low potassium.
- Pregnancy: use only if the benefit outweighs the risk. Newborns exposed in the third trimester can have movement or withdrawal symptoms.
- Older adults may be more sensitive and more prone to low white blood cell counts.
- If you reacted badly to another phenothiazine, tell your doctor.
Thioridazine overdose
▾
Thioridazine can be toxic in overdose, and the heart is the main concern. Effects can include dangerous arrhythmias, low blood pressure, sedation, confusion, seizures and breathing problems. Get emergency help or call Poison Control right away. Heart monitoring, sometimes for several days, is needed.
What Thioridazine does in the body
▾
Thioridazine lengthens the QTc interval in a dose-related way. In a small study of healthy men, a 50 mg dose raised it by about 23 msec on average, and more may be seen in real-world patients. This effect is linked to Torsades de pointes and sudden death.
How your body processes Thioridazine
▾
Thioridazine is cleared by the CYP2D6 enzyme. People with low CYP2D6 activity had about 2.4-fold higher peak levels and 4.5-fold higher total exposure in one study. Drugs that block this enzyme can raise levels in a similar way. Fluvoxamine raised thioridazine and its active metabolites about 3-fold.
How to store Thioridazine
▾
Store at 20° to 25°C (68° to 77°F). DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Thioridazine
168 supplements and herbal products have documented interactions with Thioridazine in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 11
- Moderate · 125
- Minor · 32
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Thioridazine: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Thioridazine — the kind of thing our pharmacy team would talk through with you at the counter.
Why was I prescribed thioridazine instead of something newer?
▾
How do I take it?
▾
What side effects are normal?
▾
What symptoms mean I should get help right away?
▾
Can I take it with my other medicines?
▾
Is it safe in pregnancy?
▾
Is Thioridazine available over the counter?
▾
When was Thioridazine first available?
▾
Who makes Thioridazine?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Thioridazine on HelloPharmacist
Thioridazine forms and strengths (how it comes)
Thioridazine is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Thioridazine inactive ingredients by manufacturer.
Tablet
How this form is used
- Thioridazine Hydrochloride tablets are used to manage schizophrenia in people who haven't responded adequately to other antipsychotic drugs.
- Thioridazine Hydrochloride tablets are taken by mouth, with the total daily amount divided into two to four doses.
- Your prescriber will aim for the smallest effective dose for Thioridazine Hydrochloride tablets and may lower it gradually once symptoms are controlled.
Thioridazine on the U.S. market: products, makers and brands
How Thioridazine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
5 companies list 20 Thioridazine product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 1962. Brand names on the directory include Mellaril; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (2) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Thioridazine is used (Medicaid data)
A general measure of how commonly Thioridazine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Thioridazine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Thioridazine prescribed? Of the 1,601 medications we measure, Thioridazine ranks #1,130 by Medicaid prescriptions — more than 29% of them.
Utilization by Thioridazine product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
thioridazine 50 MG Oral Tablet Most dispensed
Summed across the 1 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 198275
thioridazine 25 MG Oral Tablet
Summed across the 1 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 198274
thioridazine 100 MG Oral Tablet
Summed across the 1 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 198270
thioridazine 10 MG Oral Tablet
Summed across the 1 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 313354
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Thioridazine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 4 of 41 listed Thioridazine NDCs with Medicaid activity.
Compare Thioridazine products
A representative set of FDA-listed product records for Thioridazine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 10 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 25 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 50 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 100 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 10 mg | Oral | Mylan Institutional Inc. | ANDA | View NDC → |
| 25 mg | Oral | Mylan Institutional Inc. | ANDA | View NDC → |
| 50 mg | Oral | Mylan Institutional Inc. | ANDA | View NDC → |
| 100 mg | Oral | Mylan Institutional Inc. | ANDA | View NDC → |
| 10 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 25 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 50 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 100 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 10 mg | Oral | Safecor Health LLC | ANDA | View NDC → |
| 25 mg | Oral | Safecor Health LLC | ANDA | View NDC → |
| 50 mg | Oral | Safecor Health LLC | ANDA | View NDC → |
| 100 mg | Oral | Safecor Health LLC | ANDA | View NDC → |
| 10 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 25 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 50 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 100 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
Showing 20 of 20 products — FDA National Drug Code Directory. See every product, package size and price: browse all 20 Thioridazine NDCs →
Thioridazine side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Thioridazine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Thioridazine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Thioridazine FDA approval history
How Thioridazine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Thioridazine recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Thioridazine recalls since July 2021.
✅No Thioridazine recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 10502 3 dose forms · 14 strengths
-
Dose form (SCDF) Oral Solution RxCUI 374107No current FDA listingClinical drug / strength (SCD) 2 MG/MLRxCUI 2462295 MG/MLRxCUI 39299410 MG/MLRxCUI 10887830 MG/MLRxCUI 313358100 MG/MLRxCUI 313353 -
Dose form (SCDF) Oral Suspension RxCUI 374428No current FDA listingClinical drug / strength (SCD) 5 MG/MLRxCUI 31335720 MG/MLRxCUI 313352 -
Dose form (SCDF) Oral Tablet RxCUI 374108In current FDA listings
Look up RxCUI 10502 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Thioridazine supply and shortage status
Whether Thioridazine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Thioridazine costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet, Film Coated · Oral | 10 mg | $0.394 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 25 mg | $0.571 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 50 mg | $0.722 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 100 mg | $0.830 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Thioridazine brand names
Thioridazine is sold under one brand name in the FDA directory — Mellaril. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Thioridazine: manufacturers and labelers
5 companies list Thioridazine products with the FDA. By number of product records, the largest are Chartwell RX, LLC, Mylan Institutional Inc., Mylan Pharmaceuticals Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Thioridazine drug class (RxNorm)
Thioridazine belongs to the Phenothiazine class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Thioridazine page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Mylan Institutional Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →